XML 41 R26.htm IDEA: XBRL DOCUMENT
v3.6.0.2

BUSINESS SEGMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2016
Segment Reporting [Abstract] |
BUSINESS SEGMENT INFORMATION | BUSINESS SEGMENT INFORMATION The Company's DIS business provides insights through clinical testing and related services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing clinical testing services such as routine (including drugs-of-abuse) testing, gene-based and esoteric (including advanced diagnostics) testing, and anatomic pathology services, as well as related services and insights. The DIS business accounted for greater than 90% of net revenues from continuing operations in 2016, 2015 and 2014. All other operating segments include the Company's DS businesses, which consists of its risk assessment services, healthcare information technology, diagnostic products (prior to May 13, 2016), and clinical trials testing (prior to July 1, 2015) businesses. The Company's DS businesses offer a variety of solutions for life insurers, healthcare providers and others. In addition to the sale of Focus Diagnostics (see Note 6) in 2016, the Company wound down its Celera products business, which did not have a material impact on the Company's consolidated financial statements. As a result of these transactions, the Company has disposed of its diagnostics products business. During 2016, 2015 and 2014, the Company acquired certain operations of CLP, certain operations of MemorialCare, Superior Mobile Medics, Solstas, Summit Health and certain operations of Steward (see Note 5). CLP, MemorialCare, Solstas, Summit Health and Steward are included in the Company's DIS business. Superior Mobile Medics is included in all other operating segments. On April 19, 2006, the Company decided to discontinue NID’s operations. The results of operations for NID have been classified as discontinued operations for all periods presented (see Note 18). As of December 31, 2016, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States. The following table is a summary of segment information for the years ended December 31, 2016, 2015 and 2014. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the gains on disposition of businesses associated with the dispositions of Focus Diagnostics and Clinical Trials (see Note 6) . The accounting policies of the segments are the same as those of the Company as set forth in Note 2.
| 2016 |  | 2015 |  | 2014
Net revenues: |  |  |  |  |  |  |
DIS business | $ | 7,138 |  |  | $ | 6,965 |  |  | $ | 6,873 |
All other operating segments | 377 |  |  | 528 |  |  | 562 |
Total net revenues | $ | 7,515 |  |  | $ | 7,493 |  |  | $ | 7,435 |
Operating earnings (loss): |  |  |  |  |  |  |
DIS business | $ | 1,244 |  |  | $ | 1,118 |  |  | $ | 1,068 |
All other operating segments | 64 |  |  | 110 |  |  | 94 |
General corporate activities | (31 | ) |  | 171 |  |  | (179 | )
Total operating income | 1,277 |  |  | 1,399 |  |  | 983 |
Non-operating expenses, net | (191 | ) |  | (296 | ) |  | (160 | )
Income from continuing operations before income taxes and equity in earnings of equity method investees | 1,086 |  |  | 1,103 |  |  | 823 |
Income tax expense | (429 | ) |  | (373 | ) |  | (262 | )
Equity in earnings of equity method investees, net of taxes | 39 |  |  | 23 |  |  | 26 |
Income from continuing operations | 696 |  |  | 753 |  |  | 587 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | 5 |
Net income | 696 |  |  | 753 |  |  | 592 |
Less: Net income attributable to noncontrolling interests | 51 |  |  | 44 |  |  | 36 |
Net income attributable to Quest Diagnostics | $ | 645 |  |  | $ | 709 |  |  | $ | 556 |
Depreciation and amortization expense for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
DIS business | $ | 170 |  |  | $ | 212 |  |  | $ | 206 |
All other operating segments | 6 |  |  | 10 |  |  | 13 |
General corporate | 73 |  |  | 82 |  |  | 95 |
Total depreciation and amortization | $ | 249 |  |  | $ | 304 |  |  | $ | 314 |
Capital expenditures for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
DIS business | $ | 264 |  |  | $ | 243 |  |  | $ | 283 |
All other operating segments | 21 |  |  | 16 |  |  | 17 |
General corporate | 8 |  |  | 4 |  |  | 8 |
Total capital expenditures | $ | 293 |  |  | $ | 263 |  |  | $ | 308 |
Net revenues by major service for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
Routine clinical testing services | $ | 4,179 |  |  | $ | 4,078 |  |  | $ | 4,066 |
Gene-based and esoteric (including advanced diagnostics) testing services | 2,335 |  |  | 2,256 |  |  | 2,158 |
Anatomic pathology testing services | 624 |  |  | 631 |  |  | 649 |
All other | 377 |  |  | 528 |  |  | 562 |
Total net revenues | $ | 7,515 |  |  | $ | 7,493 |  |  | $ | 7,435 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration